Afdol Oral Solution 120Ml

Name: Afdol Oral Solution 120Ml
Brand: AGP PHARMA
Price: 1045

Brand : agp pharma

Rs. 1,045.00

Rs. 1,100.00

|

QUICK DELIVERY

Afdol Oral Specification

Requires Prescription (YES/NO)

Yes

Generics

Memantine Hydrochloride

Used For

Alzheimer

How it works

There is evidence that malfunctioning of glutamatergic neurotransmission, in particular at N-methyl-D-aspartate (NMDA)-receptors, contributes to both expression of symptoms and disease progression in neurodegenerative dementia. Memantine is a voltage-dependent, moderate-affinity uncompetitive NMDA-receptor antagonist. It blocks the effects of pathologically elevated tonic levels of glutamate that may lead to neuronal dysfunction .

Afdol Oral Usage And Safety

Dosage

Memantine Hydrochloride

Side Effects

Common: Headache, sleepiness, constipation, elevated liver function test, dizziness, balance disorders, shortness of breath, high blood pressure and drug hypersensitivity ; Uncommon: Tiredness, fungal infections, confusion, hallucinations, vomiting, abnormal gait, heart failure and venous blood clotting (thrombosis/thromboembolism).

Drug Interactions

L-dopa, dopaminergic agonists, and anticholinergics , antispasmodic medicines, dantrolene or baclofen , amantadine , cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine , hydrochlorothiazide (HCT) , dextromorphan , oral anticoagulants .

Indication

Treatment of patients with moderately severe to severe Alzheimer’s disease .

When not to Use

Hypersensitivity to memantine hydrochloride or to any of the excipients . Children and adolescents below the age of 18 years, as safety and efficacy have not been established.

Afdol Oral Precautions

Precaution

Based on pharmacological considerations and single case reports, caution is recommended with patients suffering from epilepsy.

Afdol Oral Warnings

Warning 1

Concomitant use of N-methyl-D-aspartate (NMDA)-antagonists such as amantadine, ketamine or dextromethorphan should be avoided. These medicines act at the same receptor system as this product and therefore adverse drug reactions (mainly CNS-related) may be more frequent or more pronounced .

Warning 2

In most clinical trials with Memantine, patients with recent myocardial infarction, congestive heart failure (NYHA III-IV) and uncontrolled hypertension were excluded. As a consequence only limited data are available and patients with these conditions should be closely supervised.

Warning 3

Moderately severe to severe Alzheimer’s disease usually causes impairment of driving performance and compromises the ability to use machinery. Furthermore, Memantine may change reactivity such that outpatients should be warned to take special care when driving a vehicle or operating machinery.

Download the Dvago App